Bringing Equity and Efficacy Together in Triple-Negative Breast Cancer: A Practical Guide for the Oncology Nurse

September 10, 2022

This Oncology Nursing Society (ONS) Chapter initiative is targeted to oncology nurses and nurse practitioners, specifically those practicing in the southeastern United States. Strategically designed to foster an understanding of both the disease state complexity and far-reaching racial disparity intrinsic to triple-negative breast cancer (TNBC), this educational session will begin with an appraisal of TNBC pathophysiology and the multifaceted etiologies of the disparate outcomes seen among African-American patients. Expert faculty will then guide attendees through a real-world exploration of antibody-drug conjugates, including structure, mechanism of action, and a dedicated focus on the effective anticipation, recognition, and mitigation of adverse events. Finally, attendees will take part in an interactive case-based discussion centered on how the oncology nurse can provision patient-centric care that is both efficacious and equitable through the incorporation of novel therapeutic approaches and the adoption of renewed perspectives.

Target Audience

Oncology Nurse Specialists, Registered Nurses, Nurse Practitioners

Learning Objectives

  • Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies oncology nurses can employ to promote equitable care and outcomes for all patients.
  • Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, with a particular focus on toxicity management, for oncology nurses who care for TNBC patients receiving ADCs.
  • Examine completed, ongoing, and planned clinical trial data for ADCs as part of the expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
  • Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus, strategies for anticipating, recognizing, and treating adverse events, and effectively integrating socioeconomic and other non-biologic factors into equitable cancer care.

Supported through an independent educational grant from Gilead.

Presented by Creative Educational Concepts, LLC.

Additional Information

AttachmentSize
PDF icon General Information734.21 KB
PDF icon Handout and References3.17 MB
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
06/09/2022
Course expires: 
10/10/2022
Event starts: 
09/10/2022 - 5:00am EDT
Event ends: 
09/10/2022 - 6:00am EDT
Rating: 
0

5 min     Welcome and Introductions/Pre-test

15 min   Delineating the Disparity in TNBC: A Renewed Outlook on an Established Problem

20 min   Demystifying Antibody-Drug Conjugates: The Role of the Oncology Nurse in the Evolving TNBC

              Paradigm

15 min   Closing the TNBC Outcomes Chasm: Nursing Perspectives on Novel Therapeutics and Patient-

              Centered Care

5 min     Conversations with the Experts/Audience Q&A/Post-test

Greater LA ONS
JW Marriott LA Live
Los Angeles, CA
United States

Jennifer A. McKenna, NP
Acute Care Nurse Practitioner
Dana-Farber
Brigham and Woman's Cancer Center's
Breast Oncology Program
Boston, MA

 

 

Jennifer is a nurse practitioner in the breast oncology unit at Dana Farber Cancer Institute. She trained at Yale School of Nursing as an acute care NP with a focus in oncology. She has been in practice for 20 years.


It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:
Jennifer A. McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty:
Elahe Salehi, DNP, ANP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:
Lauren Olalde, RN–is on the speakers' bureau for Trodelvy.

CEC Staff:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, CBCN®, and CPHON® nurses may apply 1.0 point in Care Continuum, Coordination of Care, Diagnosis and Staging, Nursing Practice, Oncology Nursing Practice, Psychosocial Dimensions of Care, Symptom Management, and Treatment categories. 

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. 

 

 

 

Available Credit

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.